696 related articles for article (PubMed ID: 26890292)
21. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant Therapy Use and Survival in Stage II Endometrial Cancer.
Lester-Coll NH; Young MR; Park HS; Ratner ES; Litkouhi B; Damast S
Int J Gynecol Cancer; 2017 Nov; 27(9):1904-1911. PubMed ID: 28763364
[TBL] [Abstract][Full Text] [Related]
23. Utilization of adjuvant therapies and their impact on survival for women with stage IIIC endometrial adenocarcinoma.
Wong AT; Rineer J; Lee YC; Schwartz D; Safdieh J; Weiner J; Choi K; Schreiber D
Gynecol Oncol; 2016 Sep; 142(3):514-9. PubMed ID: 27421751
[TBL] [Abstract][Full Text] [Related]
24. The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma.
Tanner EJ; Leitao MM; Garg K; Chi DS; Sonoda Y; Gardner GJ; Barakat RR; Jewell EL
Gynecol Oncol; 2011 Dec; 123(3):548-52. PubMed ID: 21945551
[TBL] [Abstract][Full Text] [Related]
25. Utilization and survival outcomes of sequential, concurrent and sandwich therapies for advanced stage endometrial cancers by histology.
Ko EM; Brensinger CM; Cory L; Giuntoli RL; Haggerty AF; Latif NA; Aviles D; Martin L; Morgan MA; Lin LL
Gynecol Oncol; 2020 Nov; 159(2):394-401. PubMed ID: 32800655
[TBL] [Abstract][Full Text] [Related]
26. Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy.
Mundt AJ; McBride R; Rotmensch J; Waggoner SE; Yamada SD; Connell PP
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1145-53. PubMed ID: 11483323
[TBL] [Abstract][Full Text] [Related]
27. Stage IVB endometrial cancer confined to the abdomen: is chemotherapy superior to radiotherapy?
Cirik DA; Karalok A; Ureyen I; Tasci T; Koc S; Turan T; Tulunay G
Eur J Gynaecol Oncol; 2016; 37(2):226-31. PubMed ID: 27172750
[TBL] [Abstract][Full Text] [Related]
28. Management of aggressive histologic variants of endometrial carcinoma at the Tom Baker Cancer Centre between 1984 and 1994.
Craighead PS; Sait K; Stuart GC; Arthur K; Nation J; Duggan M; Guo D
Gynecol Oncol; 2000 May; 77(2):248-53. PubMed ID: 10785473
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant treatment and analysis of failures in patients with high-risk FIGO Stage Ib-II endometrial cancer: an Italian multicenter retrospective study (CTF study).
Gadducci A; Cosio S; Landoni F; Maggino T; Zola P; Sostegni B; Bellicini A; Fuso L; Cristofani R; Sartori E
Gynecol Oncol; 2014 Jul; 134(1):29-35. PubMed ID: 24769176
[TBL] [Abstract][Full Text] [Related]
30. A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma.
Cantrell LA; Havrilesky L; Moore DT; O'Malley D; Liotta M; Secord AA; Nagel CI; Cohn DE; Fader AN; Wallace AH; Rose P; Gehrig PA
Gynecol Oncol; 2012 Oct; 127(1):22-6. PubMed ID: 22727985
[TBL] [Abstract][Full Text] [Related]
31. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS
Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418
[TBL] [Abstract][Full Text] [Related]
32. Improved survival endpoints with adjuvant radiation treatment in patients with high-risk early-stage endometrial carcinoma.
Elshaikh MA; Vance S; Suri JS; Mahan M; Munkarah A
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):351-6. PubMed ID: 24411608
[TBL] [Abstract][Full Text] [Related]
33. Lymphadenectomy and Adjuvant Therapy Improve Survival with Uterine Carcinosarcoma: A Large Retrospective Cohort Study.
Versluis MAC; Pielsticker C; van der Aa MA; de Bruyn M; Hollema H; Nijman HW
Oncology; 2018; 95(2):100-108. PubMed ID: 29791913
[TBL] [Abstract][Full Text] [Related]
34. Oncological Outcomes of Stage II Endometrial Cancer: A Retrospective Analysis of 250 Cases.
Ozgul N; Boyraz G; Salman MC; Gultekin M; Yuce K; Ibrahimov A; Erturk A; Gungorduk K; Gulseren V; Sanci M; Turkmen O; Karalok A; Kimyon G; Turan T; Ozkan NT; Meydanli MM; Gungor T; Ayik H; Simsek T
Int J Gynecol Cancer; 2018 Jan; 28(1):161-167. PubMed ID: 28930810
[TBL] [Abstract][Full Text] [Related]
35. The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis.
Qu XM; Velker VM; Leung E; Kwon JS; Elshaikh MA; Kong I; Logie NA; Mendez LC; van der Putten LJ; Donovan EK; Munkarah AR; Wiebe EM; Parra-Herran C; Warner A; Louie AV; D'Souza DP
Gynecol Oncol; 2018 May; 149(2):283-290. PubMed ID: 29544706
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.
Young MR; Higgins SA; Ratner E; Yu JB; Mani S; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Damast S
Int J Gynecol Cancer; 2015 Mar; 25(3):431-9. PubMed ID: 25621409
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study.
Mahdi H; Rose PG; Elshaikh MA; Munkarah A; Isrow D; Singh S; Waggoner S; Ali-Fehmi R; Morris RT; Harding J; DeBenardo R
Gynecol Oncol; 2015 Mar; 136(3):529-33. PubMed ID: 25575483
[TBL] [Abstract][Full Text] [Related]
38. Is there any benefit of paraaortic field irradiation in pelvic lymph node positive endometrial cancer patients? A propensity match analysis.
Onal C; Yuce Sari S; Akkus Yildirim B; Gultekin M; Guler OC; Yildiz F
J Obstet Gynaecol; 2020 Oct; 40(7):1012-1019. PubMed ID: 31793400
[TBL] [Abstract][Full Text] [Related]
39. Impact of adjuvant treatment on outcome in high-risk early-stage endometrial cancer: a retrospective three-center study.
Helpman L; Perri T; Lavee N; Hag-Yahia N; Chariski HA; Kalfon S; Derazne E; Beiner ME; Kadan Y; Fishman A; Korach J; Covens A; Gien L
Int J Gynecol Cancer; 2019 Jan; 29(1):133-139. PubMed ID: 30640695
[TBL] [Abstract][Full Text] [Related]
40. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer.
Kiess AP; Damast S; Makker V; Kollmeier MA; Gardner GJ; Aghajanian C; Abu-Rustum NR; Barakat RR; Alektiar KM
Gynecol Oncol; 2012 Nov; 127(2):321-5. PubMed ID: 22850412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
